To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

High expression of stroma… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

High expression of stromal PDGFR beta is associated with reduced benefit of tamoxifen in breast cancer

Journal article
Authors J. Paulsson
L. Ryden
C. Strell
O. Frings
N. P. Tobin
T. Fornander
J. Bergh
Göran Landberg
O. Stal
A. Ostman
Published in Journal of Pathology Clinical Research
Volume 3
Issue 1
Pages 38-43
ISSN 2056-4538
Publication year 2017
Published at Institute of Biomedicine, Department of Pathology
Sahlgrenska Cancer Center
Pages 38-43
Language en
Links 10.1002/cjp2.56
Keywords breast cancer, tamoxifen, tumour stroma, PDGFR beta, term-follow-up, growth-factor, tumor microenvironment, adjuvant, tamoxifen, receptor expression, resistance, chemotherapy, fibroblasts, sensitivity, inhibition
Subject categories Cancer and Oncology

Abstract

Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signalling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFR beta is an important regulator of fibroblasts. Experimental studies have linked PDGFR beta-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFR beta-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomised studies analysing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFR beta, which was not observed in the group with high stromal PDGFR beta. In general terms these findings provide novel evidence, derived from analyses of randomised clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFR beta as a marker related to tamoxifen benefit in early breast cancer.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?